ProBioGen Plans Expansion

September 9, 2014
BioPharm International Editors

ProBioGen, a biopharmaceutical drug manufacturer in Berlin, spends ?20 million to double its workforce.

ProBioGen AG announced that it will be investing €20 million to double its workforce in Berlin. ProBioGen develops novel biotechnological processes for the production of biopharmaceutical drug substances to treat serious diseases. The company specializes in cell line and process development up to GMP contract manufacturing and develops technologies to improve biotechnologically active substances. ProBioGen plans to exploit its internal potential for the development of production cell lines, process engineering, and GMP manufacturing of biopharmaceuticals.

"Together with our parent company, we will continue to expand and invest in Berlin," stated Wieland Wolf, CEO, in a press release. "With an investment of around 20 million euros, we will strengthen our market position, add two additional disposable 1000L bioreactors and, within the next two years, will double our staff from currently 75 highly skilled and dedicated employees."

Source: ProBioGen